TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced the publication of a peer-reviewed article in Cancers detailing preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study demonstrated that TTX-MC138 accumulated in metastatic bone lesions following systemic administration, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Repeated dosing was well tolerated, with no observed systemic toxicity.
The findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. The company believes these results suggest potential applicability across additional metastatic disease settings. The full press release can be viewed at https://ibn.fm/E6gbq.
The study's outcomes are particularly significant given the challenges in treating bone metastases, a common and debilitating complication of advanced breast cancer. Bone metastases can lead to severe pain, fractures, and other skeletal-related events, and current treatment options are often limited. The ability of TTX-MC138 to target and accumulate in metastatic lesions, while demonstrating a favorable safety profile, positions it as a potential therapeutic option for patients with this difficult-to-treat condition.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress miR-10b, a well-documented biomarker of metastasis. In addition to TTX-MC138, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The publication in Cancers, a peer-reviewed journal, adds to the growing body of evidence supporting the potential of targeting miR-10b in cancer therapy. The results are expected to inform the ongoing development of TTX-MC138, with further preclinical studies and potential clinical trials planned to evaluate its efficacy in patients with metastatic cancer.
